Stocks Health care GANX
NASDAQ · Health careGain Therapeutics, Inc. (GANX)
It posted a net loss of $20.1M. At June 30, 2026 it held $13.1M in cash against $343.7K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Gain Therapeutics, Inc. does
Gain Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GANX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$20.2M | -$0.61 | n/a |
| 2024 | n/a | -$20.4M | -$0.89 | -$18.9M |
| 2023 | $55.2K | -$22.3M | -$1.71 | -$18.9M |
| 2022 | $140.1K | -$17.6M | -$1.48 | -$14.8M |
| 2021 | $165K | -$13.9M | -$1.37 | -$12.5M |
| 2021 | $28.9K | -$3.6M | -$1.33 | -$3.3M |
Latest SEC filings
What Gain Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- July 16, 2026Other event 8-K
- June 29, 2026Other event 8-K
- June 25, 2026
- May 26, 2026Other event 8-K
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- April 28, 2026
- April 28, 2026Additional proxy material DEFA14A
Questions about GANX
What does Gain Therapeutics, Inc. do?
Gain Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GANX.
Is Gain Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $20.1M.
When did Gain Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026.
Similar companies
Follow GANX
Get an email when Gain Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow GANX: get an email when it filesWhere the numbers come from
Financial figures are the values Gain Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.